The updated classifications have expanded the list of recurrent genetic abnormalities that define specific AML subgroups, now including new variant translocations involving RARA, KMT2A, MECOM, and NUP98, as well as additional rearrangements and gene mutations such as NPM1 and CEBPA (Table 1). This evidence concerns the gene KMT2A and acute myeloid leukemia.